These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 39375869

  • 1. Efficacy and safety of a fixed-dose combination of dapagliflozin and linagliptin (AJU-A51) in patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, parallel-group, placebo-controlled phase III study.
    Hong JH, Kim MJ, Min KW, Won JC, Kim TN, Lee BW, Kang JG, Kim JH, Park JH, Ku BJ, Lee CB, Kim SY, Shon HS, Lee WJ, Park JY.
    Diabetes Obes Metab; 2025 Jan; 27(1):81-91. PubMed ID: 39375869
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of cofrogliptin once every 2 weeks in Chinese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, phase 3 trial.
    Gao L, Bian F, Pan T, Jiang H, Feng B, Jiang C, Sun J, Xiao J, Yan P, Ji L.
    Diabetes Obes Metab; 2025 Jan; 27(1):280-290. PubMed ID: 39434431
    [Abstract] [Full Text] [Related]

  • 3. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD.
    JAMA Cardiol; 2021 Jul 01; 6(7):801-810. PubMed ID: 33851953
    [Abstract] [Full Text] [Related]

  • 4. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.
    Nauck M, Araki A, Hehnke U, Plat A, Clark D, Khunti K.
    Int J Clin Pract; 2018 Oct 01; 72(10):e13240. PubMed ID: 30216648
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.
    Amin NB, Frederich R, Tsamandouras N, Haggag AZ, Schuster T, Zmuda W, Palmer A, Vasas S, Buckley G, Smith TR, DuBrava SJ, Zhu Q, Johnson M.
    Diabetes Obes Metab; 2025 Jan 01; 27(1):215-227. PubMed ID: 39415344
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
    Vermeire S, Schreiber S, Rubin DT, D'Haens G, Reinisch W, Watanabe M, Mehta R, Roblin X, Beales I, Gietka P, Hibi T, Hospodarskyy I, Ritter T, Genovese MC, Kwon P, Santermans E, Le Brun FO, Barron R, Masior T, Danese S.
    Lancet Gastroenterol Hepatol; 2024 Dec 02. PubMed ID: 39637881
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials.
    Lyu YS, Hong S, Lee SE, Cho BY, Park CY.
    Cardiovasc Diabetol; 2024 Feb 15; 23(1):71. PubMed ID: 38360626
    [Abstract] [Full Text] [Related]

  • 8. Randomized, Double-Blind, Placebo-Controlled Trial on the Efficacy, Safety and Tolerability of Modified-Release Methylphenidate (MPH-MR) in Chinese Children and Adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD).
    Zheng Y, Liu H, Wang X, Li H, Ruhmann M, Mayer A, Dangel O, Ammer R.
    CNS Drugs; 2024 Dec 13. PubMed ID: 39671144
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
    Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE, VX-809 TRAFFIC and TRANSPORT study groups.
    Lancet Respir Med; 2016 Aug 13; 4(8):617-626. PubMed ID: 27298017
    [Abstract] [Full Text] [Related]

  • 10. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
    Harrison SA, Browne SK, Suschak JJ, Tomah S, Gutierrez JA, Yang J, Roberts MS, Harris MS.
    J Hepatol; 2025 Jan 13; 82(1):7-17. PubMed ID: 39002641
    [Abstract] [Full Text] [Related]

  • 11. Safety profile of dapagliflozin for type 2 diabetes: pooled analysis of clinical studies for overall safety and rare events.
    Ptaszynska A, Johnsson KM, Parikh SJ, de Bruin TW, Apanovitch AM, List JF.
    Drug Saf; 2014 Oct 13; 37(10):815-29. PubMed ID: 25096959
    [Abstract] [Full Text] [Related]

  • 12. Examining the clinical utility of lacosamide: pooled analyses of three phase II/III clinical trials.
    Chung S, Ben-Menachem E, Sperling MR, Rosenfeld W, Fountain NB, Benbadis S, Hebert D, Isojärvi J, Doty P.
    CNS Drugs; 2010 Dec 13; 24(12):1041-54. PubMed ID: 21090838
    [Abstract] [Full Text] [Related]

  • 13. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
    Watada H, Yamauchi T, Yamamoto F, Taniguchi A, Yarush L, Heilmann C, Yasui A.
    Expert Opin Drug Saf; 2020 Sep 13; 19(9):1193-1202. PubMed ID: 32552153
    [Abstract] [Full Text] [Related]

  • 14. Oral budesonide for induction of remission in ulcerative colitis.
    Sherlock ME, MacDonald JK, Griffiths AM, Steinhart AH, Seow CH.
    Cochrane Database Syst Rev; 2015 Oct 26; 2015(10):CD007698. PubMed ID: 26497719
    [Abstract] [Full Text] [Related]

  • 15. Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.
    Asgharzadeh A, Patel M, Connock M, Damery S, Ghosh I, Jordan M, Freeman K, Brown A, Court R, Baldwin S, Ogunlayi F, Stinton C, Cummins E, Al-Khudairy L.
    Health Technol Assess; 2024 Dec 26; 28(80):1-190. PubMed ID: 39673446
    [Abstract] [Full Text] [Related]

  • 16. The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial.
    Elbarbary NS, Ismail EA, El-Hamamsy MH, Ibrahim MZ, Elkholy AA.
    Diabetologia; 2024 Dec 26; 67(12):2637-2649. PubMed ID: 39271520
    [Abstract] [Full Text] [Related]

  • 17. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
    Askanase AD, D'Cruz D, Kalunian K, Merrill JT, Navarra SV, Cahuzac C, Cornelisse P, Murphy MJ, Strasser DS, Trokan L, Berkani O.
    Lancet Rheumatol; 2024 Nov 22. PubMed ID: 39586304
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A, Wyndaele JJ, Sieber P.
    Am J Geriatr Pharmacother; 2006 Mar 22; 4(1):14-24. PubMed ID: 16730617
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial.
    Malone A, Kowalski MM, Helliwell J, Lynggaard Boll S, Rovsing H, Moriat K, Castillo Mondragón A, Li Y, Prener Miller C, Reinstrup Bihlet A, Dobek C, Peck V, Wilmink M, Simon LS, Conaghan PG.
    Lancet Rheumatol; 2024 Dec 22; 6(12):e860-e870. PubMed ID: 39401503
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials.
    von Eynatten M, Gong Y, Emser A, Woerle HJ.
    Cardiovasc Diabetol; 2013 Apr 09; 12():60. PubMed ID: 23570327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.